Looking Into Gilead Sciences’s Recent Short Interest
Gilead Sciences’s (NASDAQ:GILD) short percent of float has risen 8.73% since its last report. The company recently reported…
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
Gilead Strengthens Early Pipeline In Oncology And Inflammation Through The Acquisition Of XinThera; Financial Terms Of Transaction Not Disclosed; Expect Deal To Reduce Gilead’s GAAP And Non-GAAP 2023 EPS By ~$0.12-$0.15
– Acquisition of XinThera Provides Gilead with Precision Small Molecules Focused on PARP1 and MK2 Inhibitors –
Gilead Sciences, Inc. (NASDAQ:GILD) today announced the acquisition of all outstanding shares of
American Express, Gilead Sciences And This US Oil Giant On CNBC’s ‘Final Trades’
On CNBC’s "Halftime Report Final Trades," Rob Sechan of New Edge Capital Group said Gilead Sciences, Inc. (NASDAQ: GILD) is a very defensive, steady growth play.
Johnson & Johnson Ignites CAR-T Ambitions With Licensing Pact With Cellular Biomedicine
Johnson & Johnson's (NYSE: JNJ) pharma unit Janssen
Gilead vs. CDC: The $1B Showdown Over HIV Drug Profits
Gilead Sciences Inc (NASDAQ: GILD) is reportedly looking to fight claims that it owes the U.S. government a share of over $1 billion in profits from its HIV-treatment drug Truvada that could help prevent the disease.
Expert Ratings for Gilead Sciences
Analysts have provided the following ratings for Gilead Sciences (NASDAQ:GILD) within the last quarter: Bullish Somewhat Bullish Indifferent…
Why Gilead Sciences Stock Is Falling Today
Gilead Sciences Inc (NASDAQ: GILD) reported Q1 FY23 sales decreased 4% Y/Y to $6.35 billion, slightly above the consensus of $6.33 billion, due to lower Veklury (remdesivir) sales, partially offset by increased
Gilead Sciences Sees FY23 Sales $26B-$26.5B; EPS $4.75-$5.15 Vs $5.3-$5.70 Prior Est
Guidance and Outlook
For the full-year, Gilead expects:
Total product sales between $26.0 billion and $26.5 billion, unchanged from prior guidance.
Total product sales, excluding
P/E Ratio Insights for Gilead Sciences
In the current market session, Gilead Sciences Inc. (NASDAQ:GILD) stock price is at $82.75, after a 1.18% decrease.…